Lincluden Management Ltd. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Lincluden Management Ltd. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel reports. The firm purchased 13,628 shares of the medical research company’s stock, valued at approximately $5,526,000.

A number of other hedge funds also recently bought and sold shares of the business. Tranquility Partners LLC boosted its position in Thermo Fisher Scientific by 22.0% during the second quarter. Tranquility Partners LLC now owns 2,760 shares of the medical research company’s stock worth $1,119,000 after purchasing an additional 498 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 19.6% in the second quarter. Concurrent Investment Advisors LLC now owns 4,570 shares of the medical research company’s stock valued at $1,853,000 after acquiring an additional 748 shares in the last quarter. Johnson Investment Counsel Inc. lifted its position in shares of Thermo Fisher Scientific by 0.3% in the second quarter. Johnson Investment Counsel Inc. now owns 7,947 shares of the medical research company’s stock valued at $3,222,000 after acquiring an additional 27 shares in the last quarter. Matrix Asset Advisors Inc. NY lifted its position in shares of Thermo Fisher Scientific by 36.1% in the second quarter. Matrix Asset Advisors Inc. NY now owns 21,377 shares of the medical research company’s stock valued at $8,667,000 after acquiring an additional 5,665 shares in the last quarter. Finally, 1858 Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $225,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last quarter. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $524.95 on Friday. The business has a fifty day moving average of $488.68 and a two-hundred day moving average of $447.94. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $198.23 billion, a price-to-earnings ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $593.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.